AZD-4547 is an inhibitor of FGFR that is somewhat selective for FGFR2 over FGFR1 and FGFR3; it exhibits anticancer chemotherapeutic activities. This compound is currently in clinical trials as a potential treatment for breast cancer. In breast cancer cells, AZD-4547 induces apoptosis and inhibits cellular proliferation, invasion and migration. In vivo, this compound inhibits tumor growth and metastasis.